GENERAL DESCRIPTION OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA WHO PASSED AN OPEN COMPARATIVE STUDY

Authors:

Abstract:

The article provides a general description of the etiology and pathogenesis of patients with community-acquired pneumonia who passed an open comparative study at the Kharkiv Municipal Clinical Hospital No. 25. The most likely causative agents of community-acquired pneumonia in patients of the Therapeutic Department of the Kharkiv Municipal Clinical Hospital No 25 are Streptococcus pneumoniae and mixed cultures of bacteria, with an increase in the proportion of Staphylococcus aureus. In modern conditions, when choosing the tactics of antimicrobial therapy for community-acquired pneumonia, it is necessary to consider not only the spectrum of the most likely pathogens, but also the trends in the formation of antibiotic resistance in the leading etiological groups. It is impractical to prescribe empirical antibiotic therapy for community-acquired pneumonia without establishing an etiological diagnosis.

Keywords:

community-acquired pneumonia etiology pathogenesis standard antibacterial therapy

References:

1. Zinina EP, Tsarenko SV, Lohunov DIu, Tukhvatulyn AY, Babaiants AV, Avramov AA. Rol provospalytelnykh y protyvovospalytelnykh tsytokynov pry bakteryalnoy pnevmonii. Vestnik intensivnoy terapii im. A.Y. Saltanova. 2021; 1: 77–89. [in Russian].
2. Berezniakov VI, Korzh AN, Pavlov SB, Yeroshenko GA, Shevchenko KV, Vatsenko ОV et al. The degree of involvement of the level of circulating immune complexes and red blood cells in the pathogenesis of community- acquired pneumonia. World of Medicine and Biology. 2022; 1(79): 21–24.
3. Berezniakov VI, Korzh AN, Pavlov SB, Yeroshenko GA, Shevchenko KV, Pyvovar NM. Сytokines as mediators of the immune system and their role in the pathogenesis of community-acquired pneumonia. World of Medicine and Biology. 2021; 3 (77): 33–37.
4. Eshwara V, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian Journal of Medical Research. 2020; 151(4): 287–302.
5. Huang Y, Liu A, Liang L. Diagnostic value of blood parameters for com- munity-acquired pneumonia. International Immunopharmacology. 2018; 64: 10–15.
6. Kolek V, Jakubec P, Losse S. Diagnostics and treatment of community-acquired pneumonia – simplicity is the key to success. Vnitrni Lekarstvi. 2017; 63(11): 770–775.
7. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. Med- ical Clinics of North America. 2019; 103(3): 487–501.
8. Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med. 2019 Jun 20;51(6):1–13. doi: 10.1038/s12276-019-0235-1.
9. Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacology & Therapeutics. 2021; 217: 107663.
10. Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. BioScience Trends. 2016; 10(1): 7–13.

Publication:

«World of Medicine and Biology» Vol. 18 No. 81 (2022) , с. 17-21
УДК 616.24-002-02

DOI:

https://doi.org/10.26724/2079-8334-2022-3-81-17-21